US · Healthcare · Biotechnology
EPS came in at -0.06 against a street estimate of -0.06 — a beat of 0.0%.
Analysts rate Lexicon Pharmaceuticals Inc a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $3.86.
| Fund | Stake |
|---|---|
| Artal Group S A | 39.36% |
| FMR Inc | 10.13% |
| Siren, L.L.C. | 9.96% |
| Sessa Capital, L.P | 4.03% |
| Vanguard Capital Management, LLC | 2.14% |
| Point72 Asset Management, L.P. | 1.76% |
| BlackRock Inc | 0.75% |
| Geode Capital Management, LLC | 0.71% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 LEXICON PHARMACEUTICALS, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $40.9 million in cash and equivalents plus $149.7 million in | 2026-08-06 |
| Results announced · Q3 2026 LEXICON PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $0.7 million (vs. $28.9 million in Q2 2025) • Q2 2026 N | 2026-08-06 |
| Quarterly report · Q1 2026 LEXICON PHARMACEUTICALS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Investments: $199.7 million in total liquidity (cash $38.1M, short-te | 2026-05-07 |
| Results announced · Q2 2026 LEXICON PHARMACEUTICALS Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenues: $21.1 million (Q1 2026) vs $1.3 million (Q1 2025) - Licensing | 2026-05-07 |
| Material agreement · Q2 2026 LEXICON PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • $100 million total borrowing capacity from Hercules Capital in loan and security | 2026-05-06 |
| Material agreement · Q2 2026 LEXICON PHARMACEUTICALS, INC. – FORM 8-K SUMMARY As of April 30, 2026 --- HEADLINE NUMBERS • 408,434.7 shares of Series B Convertible Preferred Sto | 2026-04-30 |
| Proxy statement · Q1 2026 LEXICON PHARMACEUTICALS, INC. – PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Election of three Class II directors: Samuel L. Barke | 2026-03-16 |
| Annual report FY2025 LEXICON PHARMACEUTICALS, INC. - 2025 10-K SUMMARY HEADLINE NUMBERS • Market cap as of June 30, 2025: approximately $170 million (stock price $0.95/s | 2026-03-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lexicon Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.